LIPID EXCHANGE INDEXES: INFORMATION CAPACITY AND CLINICAL MEANING IN THE COURSE OF VALUATION OF ATHEROGENICITY OF LIPEMIC INDEX OF BLOOD



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

In accordance with the latest researches, traditional values of the lipid exchange, such as the total cholesterol (TC), triglycerides (TG), high density lipoprotein cholesterol (HDL cholesterol), are representative of the proatherogenic blood potential not to the full extent. With the purpose of increase of the clinical information capacity of values of the lipid exchange it was proposed to use different calculating indexes. The most of well-known indexes are the representative of interrelation of main classes of lipids in the blood plasma; the other indexes are substituted markers of dimension of particles of lipoproteins. In the overview main indexes of the lipid exchange are considered, the own data are adduced that concern diapasons of variation of clinical and biochemical indexes of healthy persons and the functional interrelation of indexes with another values of the lipid exchange.

Full Text

Restricted Access

About the authors

A M Kaneva

Institute of Physiology of the Komi Science Centre

E R Bojko

Institute of Physiology of the Komi Science Centre; Medical Institute of Syktyvkar State University named after Pitirim Sorokin

References

  1. Кухарчук В.В. Лечение дислипидемии как важный фактор профилактики атеросклероза и его осложнений // Системные гипертензии. 2007. № 2. С. 35-43. [Kukharchuk V.V. Sistemnye gipertenzii, 2007, Nо 2, рр. 35-43.].
  2. Yusuf S., Hawken S., Ounpuu S., Dans T., Avezum A., Lanas F., McQueen M., Budaj A., Pais P., Varigos J., Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study // Lancet. 2004. Vol. 364, Nо 9438. P. 937-952.
  3. Walldius G. The apoB/apoA-I Ratio is a Strong Predictor of Cardiovascular Risk // Lipoproteins in Health and Diseases / Ed. S. Frank, G. Kostner. Rijeka: InTech, 2012. P. 95-148.
  4. Sniderman A.D., Jungner I., Holme I., Aastveit A., Walldius G. Errors that result from using the TC/HDL-C ratio rather than the apoB/apoA-I ratio to identify the lipoprotein related risk of vascular disease // J. Intern. Med. 2006. Vol. 259, Nо 5. P. 455-461.
  5. Johansson L., Schmidt C. Increased apoB/apoA-I ratio is predictive of peripheral arterial disease in initially healthy 58-year-old men during 8.9 years of follow-up // Angiology. 2009. Vol. 60, Nо 5. P. 539-545.
  6. Genest J. Jr., McNamara J.R., Ordovas J.M., Jenner J.L., Silberman S.R., Anderson K.M., Wilson P.W., Salem D.N., Schaefer E.J. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease // J. Am. Coll. Cardiol. 1992. Vol. 19, Nо 4. P. 792-802.
  7. Ma H., Lin H., Hu Y., Li X., He W., Jin X., Gao J., Zhao N., Gao X. Mean platelet volume in relation to carotid atherosclerosis in normotensive, euglycemic, and normolipidemic Chinese middle-aged and elderly adults // Angiology. 2014. Vol. 65, Nо 6. P. 512-518.
  8. Noël B. Premature atherosclerosis in patients with xanthelasma // J. Eur. Acad. Dermatol. Venereol. 2007. Vol. 21, Nо 9. P. 1244-1248.
  9. Shukla A., Sharma M.K., Jain A., Goel P.K. Prevention of atherosclerosis progression using atorvastatin innormolipidemic coronary artery disease patients--a controlled randomized trial // Indian Heart J. 2005. Vol. 57, Nо 6. P. 675-680.
  10. Superko H.R. Beyond LDL cholesterol reduction // Circulation. 1996. Vol. 94, Nо 10. P. 2351-2354.
  11. Lennep van J.E., Westerveld H.T., Lennep van H.W., Zwinderman A.H., Erkelens D.W., Wall van der E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events // Arterioscler. Thromb. Vasc. Biol. 2000. Vol. 20, Nо 11. P. 2408-2413.
  12. Friedewald W.T., Levy R.I., Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge // Clin. Chem. 1972. Vol. 18, Nо 6. P. 499-502.
  13. Климов А.Н. Холестерин в патогенезе атеросклероза: роль «плохого» и «хорошего» холестерина // Мед. акад. журн. 2007. Т. 7, № 1. С. 4-11. [Klimov A.N., Med. Akad. Zhurn., 2007, vol. 7, No 1. pp. 4-11.].
  14. Castelli W.P., Abbott R.D., McNamara P.M. Summary estimates of cholesterol used to predict coronary heart disease // Circulation. 1983. Vol. 67, Nо 4. P. 730-734.
  15. Grover S.A., Coupal L., Hu X.P. Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work? // JAMA. 1995. Vol. 274, Nо 10. P. 801-806.
  16. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios // Ann. Intern. Med. 1994. Vol. 121, Nо 9. P. 641-647.
  17. Лазнам С.С., Катамадзе Н.О., Берштейн Л.Л., Гришкин Ю.Н. Проблемы традиционного подхода к прогнозированию риска ишемической болезни сердца // Вестник Российской военно-медицинской академии. 2013. Т. 41, № 1. С. 45-49. [Laznam S.S., Katamadze N.O., Berstein L.L., Grishkin U.N., Vestnik Rossiiskoi voenno-medicinskoi akademii, 2013, vol. 41, No 1, pp. 45-49.].
  18. Miller M., Ginsberg H.N., Schaefer E.J. Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease // Am. J. Cardiol. 2008. Vol. 101, Nо 7. P. 1003-1008.
  19. Пупкова В.И. Гиперлипопротеинемия. Новосибирск: ЗАО «Вектор-Бест», 2006. 32 с. [Pupkova V.I. Giperlipoproteinemiya, Novosibirsk: ZAO «Vektor-Best», 2006, 32 p.].
  20. Hirsch G., Vaid N., Blumenthal R.S. Perspectives: The significance of measuring non-HDL-cholesterol // Prev. Cardiol. 2002. Vol. 5, Nо 3. P. 156-159.
  21. Li C., Ford E.S., McBride P.E., Kwiterovich P.O., McCrindle B.W., Gidding S.S. Non-high-density lipoprotein cholesterol concentration is associated with the metabolic syndrome among US youth aged 12-19 years // J. Pediatr. 2011. Vol. 158, Nо 2. P. 201-207.
  22. Onitiri A.C., Jover E. Comparative serum apolipoprotein studies in ischaemic heart disease and control subjects // Clin. Chim. Acta. 1980. Vol. 108, Nо 1. P. 25-30.
  23. Brunzell J.D., Sniderman A.D., Albers J.J., Kwiterovich P.O. Apoproteins B and A-I and coronary artery disease in humans // Arteriosclerosis. 1984. Vol. 4, Nо 2. P. 79-83.
  24. Naito H.K. The association of serum lipids, lipoproteins, and apolipoproteins with coronary artery disease assessed by coronary arteriography // Ann. Nо Y Acad. Sci. 1985. Vol. 454. P. 230-238.
  25. McQueen M.J., Hawken S., Wang X., Ounpuu S., Sniderman A., Probstfield J., Steyn K., Sanderson J.E., Hasani M., Volkova E., Kazmi K., Yusuf S; INTERHEART study investigators. Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEARTstudy): a case-control study // Lancet. 2008. Vol. 372, Nо 9634. P. 224-233.
  26. Srinivasan S.R., Berenson G.S. Serum apolipoproteins A-I and B as markers of coronary artery disease risk in early life: the Bogalusa Heart Study // Clin. Chem. 1995. Vol. 41, Nо 1. P. 159-164.
  27. Sniderman A.D., Pedersen T., Kjekshus J. Putting low-density lipoproteins at center stage in atherogenesis // Am. J. Cardiol. 1997. Vol. 79, Nо 1. P. 64-67.
  28. Sniderman A.D., Kiss R.S. The strengths and limitations of the apoB/apoA-I ratio to predict the risk of vascular disease: a Hegelian analysis // Curr. Atheroscler. Rep. 2007. Vol. 9, Nо 4. P. 261-265.
  29. Thompson A., Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies // J. Intern. Med. 2006. Vol. 259, Nо 5. P. 481-492.
  30. Millán J., Pintó X., Muñoz A., Zúñiga M., Rubiés-Prat J., Pallardo L.F., Masana L., Mangas A., Hernández-Mijares A., González-Santos P., Ascaso J.F., Pedro-Botet J. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention // Vasc. Health Risk Manag. 2009. Vol. 5. P. 757-765.
  31. Carnevale Schianca G.P., Pedrazzoli R., Onolfo S., Colli E., Cornetti E., Bergamasco L., Fra G.P., Bartoli E. ApoB/apoA-I ratio is better than LDL-C in detecting cardiovascular risk // Nutr. Metab. Cardiovasc. Dis. 2011. Vol. 21, Nо 6. P. 406-411.
  32. Kaneva A.M., Potolitsyna N.N., Bojko E.R. The apolipoprotein B/apolipoprotein A-I ratio in healthy men with normolipidemia: limits of variation and relationship with other lipid parameters // Clin Chem Lab Med. 2014. Vol. 52, Nо 12. P. e291-293.
  33. Kaneva A.M., Potolitsyna N.N., Bojko E.R., Odland J.O. The apolipoprotein B/apolipoprotein A-I ratio as a potential marker of plasma atherogenicity // Disease Markers. 2015. Article Number: 591454.
  34. Haidari M., Moghadam M., Chinicar M., Ahmadieh A., Doosti M. Apolipoprotein B as the best predictor of coronary artery disease in Iranian normolipidemic patients // Clin. Biochem. 2001. Vol. 34, Nо 2. P. 149-155.
  35. Kim H.K., Chang S.A., Choi E.K., Kim Y.J., Kim H.S., Sohn D.W., Oh B.H., Lee M.M., Park Y.B., Choi Y.S. Association between plasma lipids, and apolipoproteins and coronary artery disease: a cross-sectional study in a low-risk Korean population // Int. J. Cardiol. 2005. Vol. 101, Nо 3. P. 435-440.
  36. Канева А.М., Потолицына Н.Н., Людинина А.Ю., Алисултанова Н.Ж., Бойко Е.Р. Низкое содержание аполипопротеина-Е как фактор риска повышения соотношения аполипопротеин-В/аполипопротеин-АI у здоровых мужчин с нормолипидемией // Клиническая лабораторная диагностика. 2014. Т. 59, № 12. С. 32-36. [Kaneva A.M., Potolitsyna N.N., Liudinina A.Iu., Alisultanova N.Zh., Boĭko E.R., Klin. Lab. Diagn., 2014, vol. 59, No 12, pp. 32-36.].
  37. Wägner A.M., Jorba O., Rigla M., Alonso E., Ordóñez-Llanos J., Pérez A. LDL-cholesterol/apolipoprotein B ratio is a good predictor of LDL phenotype B in type 2 diabetes // Acta Diabetol. 2002. Vol. 39, Nо 4. P. 215-220.
  38. Yoshida A., Kouwaki M., Matsutani Y., Fukuchi Y., Naito M. Usefulness of serum total cholesterol/triglyceride ratio for predicting the presence of small, dense LDL // J. Atheroscler. Thromb. 2004. Vol. 11, Nо 4. P. 215-219.
  39. Hirano T, Ito Y, Yoshino G. Measurement of small dense low-density lipoprotein particles // J. Atheroscler. Thromb. 2005. Vol. 12, Nо 2. P. 67-72.
  40. Lamarche B., Tchernof A., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J., Despres J.P. Small dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study // Circulation. 1997. Vol. 95, Nо 1. P. 69-75.
  41. Arai H., Kokubo Y., Watanabe M., Sawamura T., Ito Y., Minagawa A., Okamura T., Miyamato Y. Small dense low-density lipoproteins cholesterol can predict incident cardiovascular disease in an urban Japanese cohort: the Suita study // J. Atheroscler. Thromb. 2013. Vol. 20, Nо 2. P. 195-203.
  42. Furuya D., Yagihashi A., Nasu S., Endoh T., Nakamura T., Kaneko R., Kamagata C., Kobayashi D., Watanabe N. LDL particle size by gradient-gel electrophoresis cannot be estimated by LDL-cholesterol/apolipoprotein B ratios // Clin. Chem. 2000. Vol. 46, Nо 8. P. 1202-1203.
  43. Décary S., Dumont G., Lamarche B., Hogue J.C., Tremblay A.J., Bergeron J., Couture P. Assessment of the validity of the frequently used lipid indices for predicting LDL peak particle diameter in a large cohort of 1955 normal and dyslipidemic subjects // Clin. Biochem. 2010. Vol. 43, Nо 4-5. P. 401-406.
  44. Kaneva A.M., Potolitsyna N.N., Bojko E.R. Usefulness of the LDL-C/apoB ratio in the overall evaluation of atherogenicity of lipid profile // Arch. Physiol. Biochem. 2017. Vol. 123, Nо 1. P. 16-22.
  45. Austin M.A., King M.C., Vranizan K.M., Newman B., Krauss R.M. Inheritance of low-density lipoprotein subclass patterns: results of complex segregation analysis // Am. J. Hum. Genet. 1988. Vol. 43, Nо 6. P. 838-846.
  46. Gazi I.F., Tsimihodimos V., Tselepis A.D., Elisaf M., Mikhailidis D.P. Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles // Expert Opin. Biol. Ther. 2007. Vol. 7, Nо 1. P. 53-72.
  47. Musunuru K. Atherogenic dyslipidemia: cardiovascular risk and dietary intervention // Lipids. 2010. Vol. 45, Nо 10. P. 907-914.
  48. Williams P.T., Krauss R.M., Kindel-Joyce S., Dreon D.M., Vranizan K.M., Wood P.D. Relationship of dietary fat, protein, cholesterol, and fiber intake to atherogenic lipoproteins in men // Am. J. Clin. Nutr. 1986. Vol. 44, Nо 6. P. 788-797.
  49. Lamon-Fava S., Fisher E.C., Nelson M.E., Evans W.J., Millar J.S., Ordovas J.M., Schaefer E.J. Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins // J. Clin. Endocrinol. Metab. 1989. Vol. 68, Nо 1. P. 17-21.
  50. Mahley R.W., Weisgraber K.H., Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS // J. Lipid Res. 2009. Vol. 50 (Suppl.). P. 183-188.
  51. Бойко Е.Р., Канева А.М. Аполипопротеин Е и его значение в клинической физиологии // Успехи физиологических наук. 2009. Т. 40, № 1. С. 3-15. [Boĭko E.R., Kaneva A.M., Usp. Fiziol. Nauk, 2009, vol. 40, No 1, pp. 3-15.].
  52. Канева А.М., Потолицына Н.Н., Бойко Е.Р. Содержание аполипопротеина-Е у жителей европейского Севера // Экология человека. 2011. № 2. С. 43-46. [Kaneva A.M., Potolitsyna N.N. Bojko E.R., Ekologiya cheloveka, 2011, No 2, pp. 43-46.].
  53. Kaneva A.M., Bojko E.R., Potolitsyna N.N., Odland J.O. Plasma levels of apolipoprotein-E in residents of the European North of Russia // Lipids Health Dis. 2013. Vol. 12. Article Number: 43.
  54. Kaneva A.M., Potolitsyna N.N. Bojko E.R. Concentration of apolipoprotein-E in high density lipoproteins of human blood plasma // Arch. Biol. Sci. 2013. Vol. 65, Nо 3. P. 939-944.
  55. Dobiasova M., Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FER(HDL)) // Clin. Biochem. 2001. Vol. 34, Nо 7. P. 583-588.
  56. Bittner V., Johnson B.D., Zineh I., Rogers W.J., Vido D., Marroquin O.C., Bairey-Merz C.N., Sopko G. The triglyceride/high-density lipoprotein cholesterol ratio predicts all-cause mortality in women with suspected myocardial ischemia: a report from the Women's Ischemia Syndrome Evaluation (WISE) // Am. Heart J. 2009. Vol. 157, Nо 3. P. 548-555.
  57. Wen J.H., Zhong Y.Y., Wen Z.G., Kuang C.Q., Liao J.R., Chen L.H., Wang P.S., Wu Y.X., Ouyang C.J., Chen Z.J. Triglyceride to HDL-C ratio and increased arterial stiffness in apparently healthy individuals // Int. J. Clin. Exp. Med. 2015. Vol. 8, Nо 3. P. 4342-4348.
  58. Tan M.H., Johns D., Glazer N.B. Pioglitazone reduces atherogenic index of plasma in patients with type 2 diabetes // Clin. Chem. 2004. Vol. 50, Nо 7. P. 1184-1188.
  59. Dobiásová M. Atherogenic index of plasma [log(triglycerides/HDL-cholesterol)]: theoretical and practical implications // Clin. Chem. 2004. Vol. 50, Nо 7. P. 1113-1115.
  60. Dobiásová M., Raslová K., Rauchová H., Vohnout B., Ptácková K., Frohlich J. Atherogenic lipoprotein profile in families with and without history of early myocardial infarction // Physiol. Res. 2001. Vol. 50, Nо 1. P. 1-8.
  61. Dobiásová M., Urbanová Z., Samánek M. Relations between particle size of HDL and LDL lipoproteins and cholesterol esterification rate // Physiol. Res. 2005. Vol. 54, Nо 2. P. 159-165.
  62. Dobiásová M. AIP - atherogenic index of plasma as a significant predictor of cardiovascular risk: from research to practice // Vnitr. Lek. 2006. Vol. 52, Nо 1. P. 64-71.
  63. Niroumand S., Khajedaluee M., Khadem-Rezaiyan M., Abrishami M., Juya M., Khodaee G., Dadgarmoghaddam M. Atherogenic Index of Plasma (AIP): A marker of cardiovascular disease // Med. J. Islam. Repub. Iran. 2015. Vol. 29. Article Number: 240.
  64. Zhu X.W., Deng F.Y., Lei S.F. Meta-analysis of Atherogenic Index of Plasma and other lipid parameters in relation to risk of type 2 diabetes mellitus // Prim. Care Diabetes. 2015. Vol. 9, Nо 1. P. 60-67.
  65. Onat A., Can G., Kaya H., Hergenc G. “Atherogenic index of plasma” (log10 triglyceride/high-density lipoprotein-cholesterol) predicts high blood pressure, diabetes and vascular events // J. Clin. Lipidol. 2010. Vol. 4, Nо 2. P. 89-98.
  66. Ezeukwu A.O., Agwubike E.O. Anthropometric measures of adiposity as correlates of atherogenic index of plasma in non-obese sedentary Nigerian males // Libyan J. Med. 2014. Vol. 9. P. 23798.
  67. Saeedi R., Johns K., Frohlich J., Bennett M.T., Bondy G. Lipid lowering efficacy and safety of Ezetimibe combined with rosuvastatin compared with titrating rosuvastatin monotherapy in HIV-positive patients // Lipids Health Dis. 2015. Vol. 14. Article Number: 57.
  68. Kucera M., Oravec S., Hirnerova E., Huckova N., Celecova Z., Gaspar L., Banach M. Effect of atorvastatin on low-density lipoprotein subpopulations and comparison between indicators of plasma atherogenicity: a pilot study // Angiology. 2014. Vol. 65, Nо 9. P. 794-799.
  69. Christodoulakos G.E., Lambrinoudaki I.V., Economou E.V., Papadias C., Panoulis C.P., Kouskouni E.E., Vlachou S.A., Creatsas G.C. Differential effect of hormone therapy and tibolone on lipids, lipoproteins, and the atherogenic index of plasma // J. Cardiovasc. Pharmacol. 2006. Vol. 47, Nо 4. P. 542-548.
  70. Høstmark A.T., Osland A., Simonsen S., Levorstad K. Lipoprotein-related coronary risk factors in patients with angiographically defined coronary artery disease: relation to number of stenosed arteries // J. Intern. Med. 1990. Vol. 228, Nо 4. P. 317-321.
  71. Berg J.E., Høstmark A.T. Cardiovascular risk determination: discrepancy between total cholesterol evaluation and two compound laboratory indices in Norway // J. Epidemiol. Community Health. 1994. Vol. 48, Nо 4. P. 338-343.
  72. Berg J.E. A comparison of cardiovascular risk as measured by compound blood lipid indices and two indices including lifestyle factors in occupational health service // Occup. Med. (Lond). 1996. Vol. 46, Nо 4. P. 299-303.
  73. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein A-I determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study // Clin. Chem. 1996. Vol. 42, Nо 4. P. 507-514.
  74. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W., Massov T., Schaefer E.J. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study // Clin. Chem. 1996. Vol 42, Nо 4. P. 515-523.
  75. Канева А.М. Атерогенный индекс (ATH index) - комплексный показатель липидного обмена // Новая наука: от идеи к результату. 2016. № 10-2. С. 27-29. [Kaneva A.M., Novaya nauka: ot idei k rezultatu, 2016, No 10-2, pp. 27-29.].

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2017 Kaneva A.M., Bojko E.R.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 74760 от 29.12.2018 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies